Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study
Titel:
Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study
Auteur:
Reinmuth, N. Cho, B.C. Lee, K.H. Luft, A. Ahn, M.-J. Schneider, J. Shepherd, F.A. Geater, S.L. Pápai-Székely, Z. Van Ngoc, T. Garassino, M.C. Liu, F. Clemett, D. Thiyagarajah, P. Ouwens, M. Scheuring, U. Peters, S. Rizvi, N.